Literature DB >> 30719623

Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?

M L Tanda1, E Piantanida1, E Masiello1, C Cusini1, L Bartalena2.   

Abstract

Entities:  

Keywords:  Cyclosporine; Graves’ orbitopathy; Intravenous glucocorticoids; Methotrexate

Mesh：

Substances：

Year:  2019        PMID： 30719623     DOI： 10.1007/s40618-019-01015-8

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  8 in total

1.  Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?

Authors:  E Piantanida; L Bartalena
Journal:  J Endocrinol Invest       Date:  2017-06-20       Impact factor: 4.256

2.  Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.

Authors:  Rathie Rajendram; Peter N Taylor; Victoria J Wilson; Nicola Harris; Olivia C Morris; Marjorie Tomlinson; Sue Yarrow; Helen Garrott; Helen M Herbert; Andrew D Dick; Anne Cook; Rao Gattamaneni; Rajni Jain; Jane Olver; Steven J Hurel; Fion Bremner; Suzannah R Drummond; Ewan Kemp; Diana M Ritchie; Nichola Rumsey; Daniel Morris; Carol Lane; Nachi Palaniappan; Chunhei Li; Julie Pell; Robert Hills; Daniel G Ezra; Mike J Potts; Sue Jackson; Geoffrey E Rose; Nicholas Plowman; Catey Bunce; Jimmy M Uddin; Richard W J Lee; Colin M Dayan
Journal:  Lancet Diabetes Endocrinol       Date:  2018-01-31       Impact factor: 32.069

3.  Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Authors:  George J Kahaly; Michaela Riedl; Jochem König; Susanne Pitz; Katharina Ponto; Tanja Diana; Elena Kampmann; Elisa Kolbe; Anja Eckstein; Lars C Moeller; Dagmar Führer; Mario Salvi; Nicola Curro; Irene Campi; Danila Covelli; Marenza Leo; Michele Marinò; Francesca Menconi; Claudio Marcocci; Luigi Bartalena; Petros Perros; Wilmar M Wiersinga
Journal:  Lancet Diabetes Endocrinol       Date:  2018-01-31       Impact factor: 32.069

4.  Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.

Authors:  M F Prummel; M P Mourits; A Berghout; E P Krenning; R van der Gaag; L Koornneef; W M Wiersinga
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

Review 5.  Efficacy and safety of orbital radiotherapy for graves' orbitopathy.

Authors:  Maria Laura Tanda; Luigi Bartalena
Journal:  J Clin Endocrinol Metab       Date:  2012-09-07       Impact factor: 5.958

6.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

Review 7.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

8.  Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.

Authors:  Zuzana Sipkova; Elizabeth A Insull; Joel David; Helen E Turner; Shay Keren; Jonathan H Norris
Journal:  Clin Endocrinol (Oxf)       Date:  2018-09-11       Impact factor: 3.478
  8 in total
  2 in total

Review 1.  Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-17       Impact factor: 5.555

2.  Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy.

Authors:  Liyun Shen; Lei Ye; Wei Zhu; Qin Jiao; Yulin Zhou; Shu Wang; Weiqing Wang; Guang Ning
Journal:  Eur Thyroid J       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.